Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project
Simone Ragaini(University of Turin), Simone Ferrero(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Maria Fátima das Graças Fernandes da Silva(Universidade Federal de São Carlos), Stephan Stilgenbauer(Universität Ulm), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Mats Jerkeman(Skåne University Hospital), P Klener(Charles University), Eva Hoster(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Andrea Evangelista(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Paula Gameiro(IPO Porto), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Ulrich Mey(Kantonsspital Graubünden), Martin Dreyling(LMU Klinikum), Mouhamad Khouja(University Hospital Schleswig-Holstein), Beat Schaefer(University Hospital Zurich), Eva Giné(Aristotle University of Thessaloniki), Elisa Genuardi(University of Turin), Daniela Drandi(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Carsten Utoft Niemann(University of Copenhagen), Ramón García‐Sánz(Centro de Investigación del Cáncer), Eva Froňková(Charles University), Marco Ladetto(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Sı́lvia Beà(Departament de Salut), Katja Gutmair(Zimmer Biomet (Germany)), Philipp Nakov(University Hospital Schleswig-Holstein), Melania Celli(Ospedale Infermi di Rimini), Christiane Pott(University Hospital Schleswig-Holstein), Jana Nabki(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Christa Homburg(Sanquin), Bashar AL Deeban(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Jeanette K. Doorduijn(Erasmus MC Cancer Institute)
Cited by 1
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k